Anteris Technologies Global (NASDAQ:AVR – Get Free Report) and Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.
Volatility & Risk
Anteris Technologies Global has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.
Earnings and Valuation
This table compares Anteris Technologies Global and Tandem Diabetes Care”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anteris Technologies Global | $1.91 million | 498.42 | -$94.14 million | ($2.23) | -4.39 |
| Tandem Diabetes Care | $1.01 billion | 1.03 | -$204.71 million | ($1.40) | -10.93 |
Anteris Technologies Global has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and target prices for Anteris Technologies Global and Tandem Diabetes Care, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anteris Technologies Global | 1 | 0 | 4 | 0 | 2.60 |
| Tandem Diabetes Care | 1 | 10 | 9 | 1 | 2.48 |
Anteris Technologies Global presently has a consensus target price of $16.00, indicating a potential upside of 63.60%. Tandem Diabetes Care has a consensus target price of $29.84, indicating a potential upside of 95.05%. Given Tandem Diabetes Care’s higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than Anteris Technologies Global.
Profitability
This table compares Anteris Technologies Global and Tandem Diabetes Care’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anteris Technologies Global | -5,148.78% | -124.76% | -101.21% |
| Tandem Diabetes Care | -9.20% | -53.88% | -7.88% |
Summary
Tandem Diabetes Care beats Anteris Technologies Global on 8 of the 13 factors compared between the two stocks.
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
